China Historical Income Statement
| CPHI Stock | USD 0.20 0.01 5.26% |
Historical analysis of China Pharma income statement accounts such as Interest Expense of 350.4 K, Selling General Administrative of 1.4 M or Total Revenue of 6.7 M can show how well China Pharma Holdings performed in making a profits. Evaluating China Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of China Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining China Pharma Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether China Pharma Holdings is a good buy for the upcoming year.
China |
About China Income Statement Analysis
China Pharma Holdings Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to China Pharma shareholders. The income statement also shows China investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
China Pharma Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts China Pharma Holdings generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of China Pharma Holdings. It is also known as China Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from China Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into China Pharma Holdings current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, China Pharma's Total Operating Expenses is increasing as compared to previous years. The China Pharma's current Cost Of Revenue is estimated to increase to about 14.4 M, while Selling General Administrative is projected to decrease to under 1.4 M.
China Pharma income statement Correlations
Click cells to compare fundamentals
China Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 171.9K | 2.7M | 3.1M | 2.7M | 2.8M | 2.9M | |
| Interest Expense | 321.7K | 294.2K | 542.0K | 434.6K | 333.6K | 350.4K | |
| Selling General Administrative | 2.3M | 1.8M | 1.7M | 1.9M | 1.5M | 1.4M | |
| Total Revenue | 10.9M | 10.9M | 9.6M | 8.1M | 7.0M | 6.7M | |
| Gross Profit | 1.5M | 2.0M | 349.3K | (493.9K) | (504.9K) | (479.6K) | |
| Other Operating Expenses | 14.3M | 13.3M | 12.8M | 5.5M | 9.8M | 12.3M | |
| Operating Income | (3.4M) | (2.5M) | (3.1M) | (3.5M) | (2.8M) | (2.6M) | |
| Ebit | (605.1K) | (2.6M) | (2.9M) | (3.5M) | (2.7M) | (2.6M) | |
| Ebitda | (433.3K) | 106.9K | 230.3K | (837.7K) | 8.4K | 8.0K | |
| Total Operating Expenses | 4.9M | 4.4M | 3.5M | 3.1M | 2.5M | 2.6M | |
| Income Before Tax | (20.7M) | (2.9M) | (3.4M) | (4.0M) | (3.1M) | (2.9M) | |
| Total Other Income Expense Net | (17.3M) | (288.5K) | (539.0K) | (423.9K) | (327.0K) | (343.3K) | |
| Net Income | (21.0M) | (3.2M) | (3.9M) | (10.2M) | (3.1M) | (2.9M) | |
| Income Tax Expense | 321.7K | 294.2K | 542.0K | 6.2M | (4.0) | (3.8) | |
| Selling And Marketing Expenses | 2.4M | 2.2M | 1.5M | 1.1M | 780.3K | 741.3K | |
| Cost Of Revenue | 9.4M | 8.9M | 9.3M | 8.6M | 7.5M | 14.4M | |
| Research Development | 229.6K | 378.0K | 319.0K | 185.9K | 240.1K | 228.1K | |
| Net Income Applicable To Common Shares | (10.8M) | (20.7M) | (2.9M) | (3.4M) | (3.1M) | (3.2M) | |
| Net Income From Continuing Ops | (20.7M) | (2.9M) | (3.4M) | (4.0M) | (3.1M) | (3.3M) | |
| Non Recurring | 15.6M | 7.1M | 17.0M | 115.2K | 132.5K | 139.1K | |
| Non Operating Income Net Other | 64.4K | 38.5K | 27.5K | 5.7K | 5.1K | 4.9K | |
| Interest Income | 27.5K | 5.7K | 3.0K | 10.8K | 5.1K | 4.8K | |
| Net Interest Income | (294.2K) | (288.5K) | (539.0K) | (423.9K) | (374.4K) | (393.2K) | |
| Reconciled Depreciation | 2.9M | 2.7M | 3.1M | 2.7M | 2.7M | 2.4M |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.